CRAIG M HORBINSKI, MD P D PERSONAL NFORMATION ......17. Burikhanov R, Shresta-Bhattarai T, Qiu S, Shukla N, Hebbar N, Lele S, , Horbinski C *Rangnekar VM. Novel mechanism of apoptosis

CRAIG M. HORBINSKI, MD, PHD

PERSONAL INFORMATION Full Name: Craig Michael Horbinski Home Address: 609 Drifter Way

Lexington, Kentucky 40509 Office Phone: (859) 257-1937 Email Address: [email protected]

EDUCATION POSTGRADUATE University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Neuropathology Fellowship, July 2009 Program Director: Clayton A. Wiley, MD, PhD

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Anatomic Pathology Residency, June 2007 Program Director: Trevor A. MacPherson, MD

University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Postdoctoral Research Fellowship, June 2004 Advisor: Charleen T. Chu, Associate Professor of Neuropathology Project: Mechanisms of oxidative stress in Parkinson Disease

GRADUATE University at Buffalo, The State University of New York School of Medicine and Biomedical Sciences, Buffalo, New York

Doctor of Philosophy (PhD), Pharmacology, May 2003 Medical Scientist Training Program (MD/PhD) Advisor: Dennis M. Higgins, PhD, Professor of Pharmacology Dissertation: Intracellular mechanisms regulating dendritic growth in rat sympathetic neurons

University at Buffalo, The State University of New York School of Medicine and Biomedical Sciences, Buffalo, New York

Doctor of Medicine (MD), Cum Laude, May 2003 Medical Scientist Training Program (MD/PhD)

UNDERGRADUATE Canisius College, Buffalo, New York

Bachelor of Science, Biology, Summa Cum Laude, May 1996

mailto:[email protected]

Craig M. Horbinski, M.D., Ph.D. 2

CERTIFICATION AND LICENSURE NEUROPATHOLOGY American Board of Pathology - September 2009 ANATOMIC PATHOLOGY American Board of Pathology - August 2007 MEDICAL LICENSURE Kentucky Board - MD - June 2009 Pennsylvania Board - MD - (inactive)

PROFESSIONAL APPOINTMENTS Associate Professor University of Kentucky July 2014-present Division of Neuropathology Department of Pathology and Laboratory Medicine Chairman: Darrell Jennings, MD Joint Appointment University of Kentucky August 2011-present Department of Molecular and Cellular Biochemistry Chairman: Doug Andres, PhD Assistant Professor University of Kentucky August 2009- Division of Neuropathology July 2014 Department of Pathology and Laboratory Medicine Chairman: Darrell Jennings, MD Business Address: 307 Combs Building 800 Rose Street Lexington, Kentucky 40536 Business Phone: (859) 257-1937 Email Address: [email protected]

PROFESSIONAL AND SCIENTIFIC SOCIETIES American Association of Cancer Researchers, 2008-present Society for Neuro-Oncology, 2008-present American Association of Neuropathologists, 2007-present United States and Canadian Academy of Pathology, 2007-present

mailto:[email protected]


HONORS AND AWARDS 1. Featured article. The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by

mutant IDH1 and kills glioma stem cells. Cancer Stem Cell News 3.32, 2014. 2. Featured article. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in

diagnoses of infiltrative glioma. www.MDLinx.com, 2014. 3. Featured article. What do we know about IDH1/2 mutations, and how do we use it?

www.MDLinx.com, 2013. 4. Featured article. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from

infiltrative gliomas. www.MDLinx.com, 2011. 5. O.T. Bailey-Helena Riggs Award for best presentation at the 50th Annual Diagnostic Slide

Session at the American Association of Neuropathologists Annual Meeting, San Antonio, TX, 2009.

6. Second place in the 18th Annual University of Pittsburgh Department of Pathology Research

Day contest for best presentation (Title: Cryptic unbalanced t(4q;18q) in a pediatric patient), 2008.

7. Second place in the 17th Annual University of Pittsburgh Department of Pathology Research

Day contest for best presentation (Title: Telepathology for intra-operative neuropathological consultations at an academic medical center: a five-year report), 2007.

8. Free Radical Biology and Medicine Most Cited Papers 2005-2007 Award for Horbinski C,

Chu CT. Kinase signaling cascades in the mitochondrion: A matter of life or death. Free Radical Biology and Medicine 38(1): 2-11, 2005.

9. Second place in the University of Pittsburgh Department of Pathology contest for best web

case (Title: A Caucasian woman in her late 20s with progressive shortness of breath), 2005. 10. Harry E. and Loretta A. Jordan Award for outstanding research in the field of ophthalmology,

2003. 11. “Highly Accessed” designation for Horbinski C, Stachowiak MK, Higgins D, Finnegan SG.

Polyethyleneimine-mediated transfection of cultured postmitotic neurons from rat sympathetic ganglia and adult human retina. BioMedCentral Neuroscience 2(1): 2, 2001.

12. Dean’s Honor List, University at Buffalo, The State University of New York, 1997. 13. James A. Gibson Anatomical Honor Society, 1997. 14. Hearst Earning Excellence Award for scientific research, University at Buffalo, The State

University of New York, 1995-1996.

http://www.mdlinx.com/




PUBLICATIONS ORIGINAL RESEARCH PAPERS AND REVIEWS (*corresponding author) 1. Pu H, Horbinski C, Hensley PJ, Matuszak EA, Atkinson T, *Kyprianou N. PARP-1

regulates epithelial-mesenchymal-transition (EMT) in prostate tumorigenesis. Carcinogenesis. 2014 Aug 30. [Epub ahead of print.] PMID: 25173886.

2. Liu Y, Gilbert MR, Kyprianou N, Rangnekar VM, *Horbinski C. The tumor suppressor

prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathologica. 2014 Aug 19. [Epub ahead of print.] PMID: 25135281. PMCID: In Process.

3. *Timoney PJ, Clark JD, Frederick PA, Krakauer M, Compton C, Horbinski C, Sokol J,

Nunery WR. Foreign body granuloma following orbital reconstruction with porous polyethylene. Ophthalmic Plastic and Reconstructive Surgery. In Press.

4. Thakkar J, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS,

*Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiology, Biomarkers, and Prevention. 2014 Jul 22. [Epub ahead of print.] PMID: 25053711.

5. Hale JS, Sinyuk M, Alvarado A, Flavahan W, Neltner JM, Hitomi M, Huang P, Wu Q, Ren

B, Sloan AE, Silverstein RL, Gladson CE, Horbinski C, Rich JN, *Lathia JD. Cancer stem cell-specific scavenger receptor CD36 drives glioblastoma progression. Stem Cells. 2014 Jul;32(7):1746-58. PMID: 24737733. PMCID: PMC4063873.

6. Chen L, Voronovich Z, Clark K, Hands I, Mannas J, Walsh M, Nikiforova MN, Durbin EB,

Weiss H, *Horbinski C. Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro-Oncology. 2014 May 23. [Epub ahead of print.] PMID: 24860178. PMCID: In Process.

7. *Nelson PT, Estus S, Abner EL, Parikh I, Malik M, Neltner JH, Ighodaro E, Wang X, Wilfred

BR, Wang LS, Kukull WA, Nandakumar K, Farman ML, Poon WW, Corrada MM, Kawas CH, Cribbs DH, Bennett DA, Schneider JA, Larson EB, Crane PK, Valladares O, Schmitt FA, Kryscio RJ, Jicha GA, Smith CD, Scheff SW, Sonnen JA, Haines JL, Pericak-Vance MA, Mayeux R, Farrer LA, Van Eldik LJ, Horbinski C, Green RC, Gearing M, Poon LW, Kramer PL, Woltjer RL, Montine TJ, Partch AB, Rajic AJ, Richmire KR, Monsell SE, Alzheimer's Disease Genetics Consortium, Schellenberg GD, Fardo DW. ABCC9 gene polymorphism is associated with hippocampal sclerosis of aging pathology. Acta Neuropathologica. 2014 Jun;127(6):825-43. PMID: 24770881. PMCID: PMC4113197.

8. Convertini P, Shen M, Potter PM, Palacios G, Lagisetti C, de la Grange P, Horbinski C,

Fondufe-Mittendorf YN, Webb TR, *Stamm S. Sudemycin E influences alternative splicing


and changes chromatin modifications. Nucleic Acids Research. 2014 Apr;42(8):4947-61. PMID: 24623796. PMCID: PMC4005683.

9. Collazo J, Zhu B, Larkin S, Horbinski C, Pu H, Koocheckpoor S, *Kyprianou N. Cofilin

drives cell-invasive and metastatic responses to TGF-β in prostate cancer. Cancer Research. 2014 Apr 15;74(8):2362-73. PMID: 24509905.

10. Gilbert MR, Liu Y, Neltner J, Pu H, Morris A, Sunkara M, Pittman T, Kyprianou N,

*Horbinski C. Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathologica. 2014 Feb;127(2):221-33. PMID: 24150401. PMCID: PMC3946987.

11. Nelter J and *Horbinski C. A 29 year-old woman with mental status changes. Brain

Pathology. 2013 Jul;23(4):479-82. PMID: 23936918. 12. *Horbinski C. What do we know about IDH1/2 mutations so far, and how do we use it?

Acta Neuropathologica. 2013 May;125(5):621-36. PMID: 23512379. PMCID: PMC3633675.

13. Clark K, Voronovich Z, *Horbinski C. How molecular testing can help (and hurt) in the

workup of gliomas. American Journal of Clinical Pathology. 2013 Mar;139(3):275-88. PMID: 23429363.

14. *Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski

C, Venneti S, Zadeh G, Santi M, Zhou S, Appin CL, Nayak L, Sioletic S, Sullivan L, Martinez-Lage1 M, Robinson A, Mueller S, Marshall R, Haas-Kogen DA, Molinaro AM, Perry A. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathology. 2013 Sep:23(5):565-73. PMID: 23438035. PMCID: PMC3715570.

15. Clark KH, Villano JL, Nikiforova MN, Hamilton RL, *Horbinski C. 1p/19q testing has no

significance in the workup of glioblastomas. Neuropathology and Applied Neurobiology. 2013 Oct 39(6):706-17. PMID: 23363074. PMCID: PMC4095883.

16. *Horbinski C. To BRAF or not to BRAF: Is that even a question anymore? Journal of

Neuropathology and Experimental Neurology. 2013 Jan;72(1):2-7. PMID: 23242278. PMCID: PMC3530158.

17. Burikhanov R, Shresta-Bhattarai T, Qiu S, Shukla N, Hebbar N, Lele S, Horbinski C,

*Rangnekar VM. Novel mechanism of apoptosis resistance in cancer mediated by extracellular PAR-4. Cancer Research. 2013 Jan 15;73(2):1011-9. PMID: 23204231. PMCID: PMC3549021.

18. *Horbinski C. Something old and something new about molecular diagnostics in gliomas.

Surgical Pathology Clinics. 2012 Dec 1;5(4): 919-939. PMCID: PMC3583362.


19. *Ellezam B, Theeler BJ, Walbert T, Mammoser AG, Horbinski C, Kleinschmidt-DeMasters BK, Perry A, Puduvalli V, Fuller GN, Bruner JB, Aldape KD. Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas limits use as a diagnostic marker. Acta Neuropathologica. 2012 Sep;124(3):449-51. PMID: 22772980. PMCID: PMC4085739.

20. *Hanaoka BY, Peterson CA, Horbinski C, Crofford LJ. Implications of glucocorticoid

therapy in idiopathic inflammatory myopathies. Nature Reviews Rheumatology. 2012 Aug;8(8):448-57. PMID: 22688888.

21. Liu Y, Yoshihiro K, Hamilton RL, Horbinski C, Ferrone S, *Okada H. Expression of

antigen processing and presenting molecules in brain metastasis of breast cancer. Cancer Immunology Immunotherapy. 2012 Jun;61(6):789-801. PMID: 22065046. PMCID: PMC3365630.

22. *Horbinski C, Nikiforova MN, Hagenkord J, Hamilton RL, Pollack IF. Interplay among

BRAF, p16, p53, and MIB1 in pediatric low grade gliomas. Neuro-Oncology. 2012 Jun;14(6):777-89. PMID: 22492957. PMCID: PMC3367847.

23. Hobbs J, Nikiforova MN, Fardo D, Bortoluzzi S, Cieply K, Hamilton RL, *Horbinski C.

Paradoxical relationship between the degree of EGFR amplification and outcome in glioblastomas. American Journal of Surgical Pathology. 2012 Aug 36(8):1186-93. PMID: 22472960. PMCID: PMC3393818.

24. *Horbinski C, Nikiforova MN, Hobbs J, Cieply K, Dacic S, Hamilton RL. The importance

of 10q status in an outcomes-based comparison between 1p/19q FISH and PCR-based microsatellite LOH analysis of oligodendrogliomas. Journal of Neuropathology and Experimental Neurology. 2012 Jan;71(1):73-82. PMID: 22157622. PMCID: PMC3246063.

25. *Horbinski C, Nikiforova M, Hobbs, J, Hamilton RL. EGFR expression stratifies

oligodendroglioma behavior. American Journal of Pathology. 2011 Oct;179(4):1638-44. PMID: 21839716. PMCID: PMC3181357.

26. *Horbinski C, Kofler J, Yeaney G, Camelo-Piragua S, Venneti S, Louis DN, Perry A,

Murdoch G, Nikiforova M. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathology. 2011 Sep;21(5):564-74. PMID: 21314850. PMCID: PMC3681126.

27. *Horbinski C, Dillon D., Pittman T. Low-grade recurrence of a congenital supratentorial

primitive neuroectodermal tumor with astrocytic features in the absence of adjuvant therapy. Neuropathology. 2011 Jun;31(3):286-91. PMID: 20880322.

28. *Horbinski C, Miller CR, Perry A. Gone FISHing: Clinical lessons learned in brain tumor

molecular diagnostics over the last decade. Brain Pathology. 2011 Jan;21(1):57-73. PMID: 21129060.


29. Zhu M, Horbinski C, Garzotto M, Qian D, Beer T and *Kyprianou N. Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Research. 2010 Oct 15;70(20):7992-8002. PMCID: PMC2978028.

30. *Horbinski C, Mojesky C, Kyprianou N. Live free or die: Tales of homeless (cells) in

cancer. American Journal of Pathology. 2010 Sep;177(3):1044-52. PMCID: PMC2928938. 31. *Horbinski C, Oakley GJ, Cieply K, Mantha GS, Nikiforova MN, Dacic S, Seethala RR.

The prognostic value of Ki-67, p53, EGFR, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas. Archives of Pathology and Laboratory Medicine. 2010 Aug;134(8):1170-6. PMID: 20670138.

32. Horbinski C, Kelly L, Nikiforov YE, Durso MB, Nikiforova MN. Detection of IDH1 and

IDH2 mutations by fluorescence melting curve analysis as a diagnostic tool for brain biopsies. Journal of Molecular Diagnostics. 2010 Jul;12(4):487-92. PMID: 20431032. PMCID: PMC2893633.

33. *Horbinski C. Practical molecular diagnostics in neuropathology: Making a tough job a

little easier. Seminars in Diagnostic Pathology. 2010 May;27(2):105-13. PMID: 20860314. 34. *Horbinski C, Hamilton RL, Nikiforov Y, Pollack IF. Association of molecular alterations,

including BRAF, with biology and outcome in pilocytic astrocytomas. Acta Neuropathologica. 2010 May;119(5):641-9. PMID: 20044755.

35. *Horbinski C, Hamilton RL, Lovell C, Burnham J, Pollack IF. Impact of morphology, MIB-

1, p53, and MGMT on outcome in pilocytic astrocytomas. Brain Pathology. 2010 May;20(3):581-8. PMID: 19832838.

36. *Horbinski C, Pollack IF, Wiley CA, Murdoch G. A 10 year-old girl with neck pain. Brain

Pathology. 2010 Mar;20(2):519-22. PMID: 20438474. 37. *Horbinski C, Wang G, Wiley CA. YKL-40 is directly produced by tumor cells and is

inversely linked to EGFR in glioblastomas. International Journal of Clinical and Experimental Pathology. 2010 Jan 1;3(3):226-37. PMID: 20224722. PMCID: PMC2836500.

38. *Horbinski C, Kofler J, Kelly LM, Murdoch GH, Nikiforova MN. Diagnostic use of

IDH1/2 mutation analysis in routine clinical testing of formalin-fixed, paraffin-embedded glioma tissues. Journal of Neuropathology and Experimental Neurology. 2009 Dec;68(12):1319-25. PMID: 19915484.

39. *Horbinski C, Wiley CA. Comparison of telepathology systems in neuropathological

intraoperative consultations. Neuropathology. 2009 Dec;29(6):655-63. PMID: 19422534.


40. *Horbinski C, Dacic S, McLendon RE, Cieply K, Datto M, Brat DJ, Chu CT. Chordoid glioma: A case report and molecular characterization of five cases. Brain Pathology. 2009 Jul;19(3):439-48. PMID: 18652591.

41. *Horbinski C, Hamilton RL. Application of telepathology for neuropathological

intraoperative consultations. Brain Pathology. 2009 Apr;19(2):317-22. PMID: 19290998. 42. Horbinski C, Bartynski WS, Carson-Walter E, Hamilton RL, Tan HP, *Cheng S. Reversible

encephalopathy after cardiac transplantation: Histologic evidence of endothelial activation, T-cell specific trafficking, and VEGF expression. American Journal of Neuroradiology. 2009 Mar;30(3):588-90. PMID: 18854444.

43. Horbinski C, Carter EM, Heard PL, Sathanoori M, Hu J, Vockley G, Gunn S, Hale DE,

*Surti U, Cody JD. Molecular and clinical characterization of cryptic unbalanced t(4q;18q) resulting in an 18q deletion and 4q duplication. American Journal of Medical Genetics. 2008 Nov 15;146A(22):2898-904. PMID: 18932219. PMCID: PMC2584776.

44. *Horbinski C, Cieply K, Bejjani GK, McFadden K. Primary intracranial dural-based

synovial sarcoma with an unusual SYT fluorescence in situ hybridization pattern. Journal of Neurosurgery. 2008 Nov;109(5):897-903. PMID: 18976081.

45. *Striebel JM, Bhargava R, Horbinski C, Surti U, Dabbs DJ. The equivocally amplified

HER2 FISH result on breast core biopsy: Indications for further sampling do affect patient management. American Journal of Clinical Pathology. 2008 Mar;129(3):383-90. PMID: 18285260.

46. *Horbinski C, Fine JL, Medina-Flores R, Yagi Y, Wiley CA. Telepathology for

intraoperative neuropathologic consultations at an academic medical center: A five-year report. Journal of Neuropathology and Experimental Neurology. 2007 Aug;66(8):750-9. PMID: 17882019.

47. Kulich SM, Horbinski C, Patel M, *Chu CT. 6-Hydroxydopamine induces mitochondrial

ERK activation. Free Radical Biology and Medicine. 2007 Aug 1;43(3):372-83. PMID: 17602953. PMCID: PMC2023873.

48. Zhu JH, Horbinski C, Guo F, Watkins S, Uchiyama Y, *Chu CT. Regulation of autophagy

by extracellular signal-regulated protein kinases during 1-methyl-4-phenylpyridinium-induced cell death. American Journal of Pathology. 2007 Jan;170(1):75-86. PMCID: PMC1762689.

49. Horbinski C, *Chu CT. Kinase signaling cascades in the mitochondrion: A matter of life

or death. Free Radical Biology and Medicine. 2005 Jan 1;38(1):2-11. PMID: 15589366. 50. †Kim W, †Horbinski C, Sigurdson W, *Higgins D. Proteasome inhibitors suppress

formation of polyglutamine-induced nuclear inclusions in cultured postmitotic neurons.


Journal of Neurochemistry. 2004 Dec;91(5):1044-56. †co-first-authorship. PMID: 15569248.

51. Garrick MD, Dolan KG, Horbinski C, Ghio A, Higgins D, Porubcin M, Moore EG,

Hainsworth LN, Umbreit JN, Conrad ME, Feng L, Lis A, Roth JA, Singleton S, *Garrick LM. DMT1: A mammalian transporter for multiple metals. Biometals. 2003 Mar;16(1): 41-54.

52. *Roth JA, Horbinski C, Higgins D, Lein P, Garrick MD. Mechanisms of manganese-

induced rat pheochromocytoma (PC12) cell death and cell differentiation. Neurotoxicology. 2002 Jul;23(2):147-57. PMID: 12224755.

53. Horbinski C, Stachowiak EK, Chandrasekaran V, Miuzukoshi E, Higgins D, *Stachowiak

MK. Bone morphogenetic protein-7 stimulates initial dendritic growth in sympathetic neurons through an intracellular fibroblast growth factor signaling pathway. Journal of Neurochemistry. 2002 Jan;80(1):54-63. PMID: 11796743.

54. Dattatreyamurty B, Roux E, Horbinski C, Kaplan PL, Robak LA, Beck HN, Lein P, Higgins

D, *Chandrasekaran V. Cerebrospinal fluid contains biologically active bone morphogenetic protein-7. Experimental Neurology. 2001 Dec;172(2):273-81. PMID: 11716552.

55. Guo X, Lin Y, Horbinski C, Drahushuk KM, Kim IJ, Kaplan PL, Lein P, Wang T, *Higgins

D. Dendritic growth induced by BMP-7 requires Smad1 and proteasome activity. Journal of Neurobiology. 2001 Aug;48(2):120-30. PMID: 11438941.

56. *Horbinski C, Stachowiak MK, Higgins D, Finnegan SG. Polyethyleneimine-mediated

transfection of cultured postmitotic neurons from rat sympathetic ganglia and adult human retina. BioMedCentral Neuroscience. 2001;2:2. PMID: 11231879. PMCID: PMC29102.

57. *Roth JA, Horbinski C, Feng L, Dolan KG, Higgins D, Garrick MD. Differential

localization of divalent metal transporter 1 with and without iron response element in rat PC12 and sympathetic neuronal cells. Journal of Neuroscience. 2000 Oct 15;20(20): 7595-601. PMID: 11027219.

NON PEER-REVIEWED MONOGRAPHS 1. Cover composite of BRAF mutations in gliomas. Horbinski C. Journal of Neuropathology

and Experimental Neurology 72(1), January 2013. 2. Horbinski C. Invited correspondence RE: diagnostic utility of IDH1/2 mutation analysis in

routine clinical testing of formalin-fixed paraffin-embedded glioma tissues. Journal of Neuropathology and Experimental Neurology 69(3): 320-321, 2010.


3. Cover composite photograph of gliomas and IDH1 mutation sequencing. Horbinski C. Journal of Neuropathology and Experimental Neurology 68(12), December 2009.

4. Horbinski C, Wiley CA. Molecular genetic analysis of oligodendroglial tumors. In: Year

Book of Pathology and Laboratory Medicine, 233-235, 2007. 5. Cover photograph of neurons. Horbinski C. Experimental Neurology 172(2), 2001.

ABSTRACTS 1. Melan MA, Wald AI, Zhong S, Hamilton R, Horbinski C, Nikiforova MN. BrainSeq: Next-

generation sequencing panel for detection of genetic alterations in central nervous system (CNS) malignancies. Association for Molecular Pathology Annual Meeting, November 12-15, 2014.

2. Schonberg DL, Flavahan WA, Das N, Hubert CG, Horbinski C, Fox PL, Rich JN. Targeting

iron metabolism in glioblastoma stem cells. Cancer Stem Cell Conference, Cleveland, OH, 2014.

3. Liu Y, Gilbert M, Kyprianou N, Rangnekar V, Horbinski C. Mutant IDH1 suppresses

apoptosis regulator par-4 in gliomas. 20th International Conference on Brain Tumor Research and Therapy (ICBRT20), Lake Tahoe, CA, July 20-23, 2014.

4. Hale J, Sloan AE, Gladson CE, Hazen SL, Horbinski C, Rich JN, Brown JM, Lathia JD.

Integration of cancer stem cell maintenance and lipid metabolism by scavenger receptors. 20th International Conference on Brain Tumor Research and Therapy (ICBRT20), Lake Tahoe, CA, July 20-23, 2014.

5. Chen L, Voronovich Z, Clark K, Hands I, Mannas J, Walsh M, Nikiforova MN, Durbin EB,

Weiss H, Horbinski C. Predicting the likelihood of an IDH1 or IDH2 mutation in patients diagnosed with infiltrative gliomas. American Association of Neuropathology Annual Meeting, Friday, Portland, OR, June 13, 2014.

6. Stewart R, Shuey D, Kaenzig T, Ferguson M, Samayoa L, Horbinski C. Prolonged ethanol

exposure adversely affects fluorescence in situ hybridization. 103rd Annual Meeting of the United States and Canadian Academy of Pathology, San Diego, CA, March 2014.

7. Liu Y., Gilbert MR., Kyprianou N., Rangnekar VM., Horbinski C. Mutant IDH1 suppresses

prostate apoptosis response-4 in gliomas. Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology, San Francisco, CA, November 23, 2013.


8. Voronovich Z., Chen L., Clark K., Walsh M., Mannas J., Horbinski C. A predictive model of IDH mutation probability in gliomas. Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology San Francisco, CA, November 23, 2013.

9. Xing F, Su H, Wang C, Chen L, Weiss H, Neltner J, Horbinski C, Stromburg A, Yang L.

LC-Morph: A morphological image signature for predicting lung cancer survival. IDeA Networks of Biomedical Research Excellence, 2013.

10. Gilbert M, Liu Y, Sunkara M, Morris A, Pittman T, Kyprianou N, Horbinski C. Effects of

D-2-hydroxyglutarate on proliferation, apoptosis, autophagy, and oxidative stress in gliomas. AANP Annual Meeting, Charleston SC, June 21, 2013. Journal of Neuropathology and Experimental Neurology, Vol. 72, No. 6 June 2013 pg. 540.

11. Pu H, Matuszak EA, Horbinski C, Atkinson TH, Hensley PJ, Larkin S, Kyprianou N. Parp-

1 loss controls prostate tumorigenesis via EMT. AACR 2013 Annual Meeting. 12. Walsh M, Xing F, Neltner J, Yang L, Horbinski C. Pilot study of digital image analysis as

a way to predict likelihood of 1p/19q codeletion in diffuse gliomas. American Association of Neuropathology Annual Meeting, Chicago, IL, June 2012.

13. Clark K, Nikiforova M, Hamilton RL, Horbinski C. Histology trumps apparent 1p/19q

codeletion in glioblastomas. American Association of Neuropathology Annual Meeting, Chicago, IL, June 2012.

14. Gilbert M, Liu Y, Morris A, Sunkara M, Kyprianou N, Horbinski C. The oncometabolite

(R)-2-hydroxyglutarate modulates stress-induced caspase activity in glioma cells. AACR 2012 Annual Meeting.

15. Horbinski C, Nikiforova MN, Hagenkord J, Hamilton RL, Pollack IF. Interplay between

BRAF, p16, p53, and MIB1 in pediatric low grade gliomas. AACR 2012 Annual Meeting. 16. Pu H, Matuszak EA, Horbinski C, Gayheart D, Atkinson TH, Mart M, Hensley PJ,

Kyprianou N. PARP-1 loss impacts normal prostate growth and tumorigenesis via effects on epithelial-mesenchymal transition (EMT). The Society for Basic Urologic Research Meeting, 2011.

17. Hobbs J, Nikiforova MN, Cieply K, Dacic S., Hamilton RL, Horbinski C. Nonlinear

relationship between EGFR amplification and response to temozolomide in glioblastomas. Society for Neuro-Oncology Annual Meeting, Orange County, CA, November 17-20, 2011.

18. Horbinski C, Nikiforova M, Hobbs J, Cieply K, Hamilton RL. Prospective comparison of

FISH versus PCR-based LOH in the evaluation of gliomas for 1p/19q codeletion. Journal of Neuropathology and Experimental Neurology 70(6): abstract #106, 2011.


19. Tucker J, Horbinski C, Yannelli J. Nuclear expression of the regulatory T cell marker Foxp3 by non-small cell lung cancer (NSCLC) tumors is positively correlated with histologic grade. Journal of Immunology, abstract #95.3, vol 184, 2010.

20. Horbinski C, Kofler J, Yeaney G, Camelo-Piragua S, Venneti S, Louis DN, Murdoch G,

Nikiforova M. Isocitrate dehydrogenase 1 mutations are adverse prognostic markers in gangliogliomas. XVIIth International Congress of Neuropathology, Salzburg, Austria. Brain Pathology 20 (suppl 1): 47, 2010.

21. Kelly L, Durso MB, Horbinski C, Mantha G, Nikiforova MN. Detection of IDH1 mutations

in gliomas using COLD PCR assay. Association for Molecular Pathology 16th Annual Meeting, San Jose, CA, November 2010.

22. Horbinski C, Wang G, Lovell C, Hamilton RL, Wiley CA. YKL-40 expression in high grade

gliomas differs according to molecular subset. Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, LA, October 2009.

23. Horbinski C, Hamilton RL, Pollack IF. Morphologic and molecular biomarkers in pilocytic

astro cytomas. American Association of Neuropathology Annual Meeting, San Antonio, TX, June 2009.

24. Horbinski C, Mintz A, Engh J, Lieberman F, Hamilton RL, Park D. Post-therapeutic

changes in the molecular profile of glioblastomas. American Society of Clinical Oncology Annual Meeting, Orlando, FL, May 2009.

25. Park DM, Prevedello DM, Gardner P, Horbinski C, Henry S, Chang YF, Carrau R,

Snyderman C, Hamilton R, Kassam AB. Clival chordoma molecular subtypes and clinical behavior. American Society of Clinical Oncology Annual Meeting, Orlando, FL, May 2009. Journal of Clinical Oncology, Vol 27, No 15S (May 20 Supplement), 2009: 10538.

26. Horbinski C, Oakley GJ, Cieply, K, Seethala RR. The prognostic value of Ki-67, p53, 1p36,

and 9p21 in skull base chordomas. United States and Canadian Academy of Pathology Annual Meeting, Boston, MA, March 2009.

27. Horbinski C, Carter EM, Heard PL, Sathanoori M, Hu J, Vockley G, Gunn S, Hale DE,

Surti U, Cody JD. Cryptic unbalanced t(4q;18q) in a pediatric patient. American Society for Investigative Pathology Annual Meeting, San Diego, CA, April 2008.

28. Horbinski C, Dacic S, McLendon RE, Cieply K, Datto M, Brat DJ, Chu CT. Chordoid

glioma: Molecular characterization of five cases. United States and Canadian Academy of Pathology Annual Meeting, Denver, CO, March 2008.

29. Kulich SM, Horbinski C, Chu CT. Role for mitochondrial superoxide in 6-

hydroxydopamine toxicity in B65 cells. Society for Neuroscience Annual Meeting, Atlanta, GA, October 2006.


30. Horbinski C, Fine JL, Medina-Flores R, Yagi Y, Wiley CA. Telepathology for intra-operative neuropathological consultations at an academic medical center: A five-year report. XVI International Congress of Neuropathology, San Francisco, CA, September 2006.

31. Kulich SM, Horbinski C, Chu CT. Characterization of 6-OHDA-elicited superoxide in

neurotoxicity. XVI International Congress of Neuropathology, San Francisco, CA, September 2006.

32. Garrick MD, Dolan KG, Ghio A, Horbinski C, Higgins D, Porubcin M, Moore EG, Hainsworth LN, Umbreit JN, Conrad ME, Feng L, Lis A, Roth JA, Singleton S, Garrick LM. DMT1 (divalent metal transporter 1): A mammalian transporter for multiple metals. The Second International Workshop on Iron and Copper, Pucon, Chile, November 2001.

33. Khani SC, Finnegan S, Young JE, Horbinski C, Vogt TM, Higgins DM, Gross K.

Regulation of rhodopsin kinase promoter in human retinal cells. Investigative Ophthalmology and Visual Science 42(4): S351, 2001.

34. Horbinski C, Stachowiak MK, Higgins D, Finnegan SG. Polyethylenimine (PEI)-mediated

transfection of sympathetic neurons in vitro. Society for Neuroscience Annual Meeting, Miami Beach, FL, October 1999.

35. Horbinski C, Stachowiak EK, Chandrasekaran V, Miuzukoshi E, Higgins D, Stachowiak

MK. BMP-7 signals through a novel intracellular FGF2-FGFR1 pathway in sympathetic neurons. Society for Neuroscience Annual Meeting, Miami Beach, FL, October 1999.

WEB-BASED PUBLICATIONS 1. Horbinski C, Bastacky S. A 60 year-old woman with elevated creatinine and BUN.

University of Pittsburgh School of Medicine Anatomic Pathology Web Case of the Month, June 2007, http://path.upmc.edu/cases/case514.html.

2. Horbinski C, Jones M. Gynecologic pathology. University of Pittsburgh School of Medicine

Anatomic Pathology Unknown Conference #20, May 2007, https://secure.opi.upmc.edu/pathunknowns/index.cfm.

3. Horbinski C, Peel R. Head and neck pathology. University of Pittsburgh School of

Medicine Anatomic Pathology Unknown Conference #16, April 2007, https://secure.opi.upmc.edu/pathunknowns/index.cfm.

4. Horbinski C, Jukic D. Dermatopathology. University of Pittsburgh School of Medicine

Anatomic Pathology Unknown Conference #9, February 2007, https://secure.opi.upmc.edu/pathunknowns/index.cfm.

http://path.upmc.edu/cases/case514.html

https://secure.opi.upmc.edu/pathunknowns/index.cfm




5. Horbinski C, Hamilton RL. Neoplastic diseases of the CNS. University of Pittsburgh School of Medicine Anatomic Pathology Unknown Conference #5, December 2006, https://secure.opi.upmc.edu/pathunknowns/index.cfm.

6. Horbinski C, Wiley CA. Viral diseases of the CNS. University of Pittsburgh School of

Medicine Anatomic Pathology Unknown Conference #4, October 2006, https://secure.opi.upmc.edu/pathunknowns/index.cfm.

7. Horbinski C, Monzon-Bordonaba F. A 60 year-old woman with breast cancer and a left

renal mass. University of Pittsburgh School of Medicine Anatomic Pathology Web Case of the Month, August 2006, http://path.upmc.edu/cases/case476.html.

8. Horbinski C, Chu CT, Finegold D, Virji MA. A 10 month-old girl with hypotonia.

University of Pittsburgh School of Medicine Clinical Pathology Web Case of the Month, August 2005, http://path.upmc.edu/cases/case435.html.

9. Horbinski C, Dacic S. A Caucasian woman in her late 20s with progressive shortness of

breath. University of Pittsburgh School of Medicine Anatomic Pathology Web Case of the Month, January 2005, http://path.upmc.edu/cases/case412.html.

PROFESSIONAL ACTIVITIES

PRESENTATIONS Extramural Invited Lectures 1. IDH1 mutations in brain cancer. Hematology-Oncology Grand Rounds, University of

Cincinnati, 8-9 am, October 10, 2014. 2. Advances in molecular diagnostics in gliomas and other cancers. Kentucky Cancer Registry

Fall Workshop, Griffin Gate Marriott, Lexington, KY, 8:30-9:15 am, September 11, 2014. 3. Mock Brain Tumor Board, American Brain Tumor Association Patient-Family Connections

Meeting & Retreat, Chicago, IL, July 26, 2014. 4. The intersection between genomics and metabolomics in glioma. Jeremy Rich Lab Retreat,

Golden Bear Lodge, 653 County Road 175, West Salem OH, July 17, 2014. 5. PI3K-Akt-mTOR in gliomas. Special course at the American Association of

Neuropathologists Annual Meeting, 8:30-9:15 am, June 12, 2014. 6. Clinical and research perspectives on IDH1 mutations in brain cancer. Department of

Pathology Seminar Series, University of Pittsburgh, 12-1 pm, October 10, 2013.







7. Oxidative and metabolic effects of IDH1 mutations in gliomas. Center for Regulatory and Environmental Analytical Metabolomics, University of Louisville, Louisville, KY, July 5, 2013.

8. How neuropathologists generate rapid diagnoses during surgery. American Brain Tumor

Association Webinar Series, June 27, 3-4 pm, 2013. 9. IDH mutations in gliomas. First International Conference on Oncology and Anticancer

Research, Paphos, Cyprus, June 10, 2013. 10. How to use molecular diagnostics in gliomas. Department of Pathology, University of

Tennessee Health Science Center, April 30, 2013. 11. CNS tumors that mimic other CNS tumors. Department of Pathology, University of

Tennessee Health Science Center, April 30, 2013. 12. Retrieval-based learning in medical school didactics. Department of Pathology, University

of Tennessee Health Science Center, April 30, 2013. 13. Effects of IDH1 mutations on redox, autophagy, and apoptosis in gliomas. Center for Cancer

Research, University of Tennessee Health Science Center, April 29, 2013. 14. A case-based practical approach to molecular testing of gliomas. Department of Pathology,

Summa Akron City Hospital, Akron, OH, October 17, 2012. 15. New kids on the glioma block: BRAF and IDH1/2. Department of Pathology, Case Western

Reserve University, Cleveland, OH, October 15, 2012. 16. Advanced molecular diagnostics in gliomas. University at Buffalo School of Medicine,

Neurology Grand Rounds, Buffalo, NY, October 4, 2012. 17. To BRAF or not to BRAF: Practical application of molecular diagnostics in gliomas. Mayo

Clinic Department of Pathology, Rochester, MN, September 24, 2012. 18. Are IDH1 mutations Par-4 the course in gliomas? Mayo Clinic Neuro-Oncology Program,

Rochester, MN, September 24, 2012. 19. Understanding general brain tumor pathology: Part I. American Brain Tumor Association

Patient and Family Conference, Chicago, IL, July 28, 2012. 20. Breakout session. Understanding brain tumor pathology at the molecular level: Part II.

American Brain Tumor Association Patient and Family Conference, Chicago, IL, July 28, 2012.

21. Clinical applications of BRAF alterations in pediatric low grade gliomas. 15th International

Symposium on Pediatric Neuro-Oncology, Toronto, ON, June 27, 2012.


22. Why are IDH1 mutations favorable prognostic markers in gliomas? Cleveland Clinic

Department of Stem Cell Biology and Regenerative Medicine Research Seminar, May 24, 2012.

23. Molecular diagnostics in diffuse gliomas. AANP-USCAP Companion Society Meeting,

Vancouver, BC, March 17, 2012. 24. The many faces of BRAF. Department of Pathology and Laboratory Medicine, Vancouver

General Hospital, Vancouver, BC, March 15, 2012. 25. Interplay between BRAF, p16, p53, and MIB1 in low grade pediatric gliomas. St. Jude

Children’s Research Hospital, Memphis, TN, February 24, 2012. 26. BRAF in pediatric low grade gliomas. Neural Tumor Research Forum, Cincinnati Children's

Hospital Medical Center, October 11, 2011. 27. Clinical and research applications of molecular diagnostics in gliomas. Norton Healthcare

Neuro-Oncology Group, Louisville, KY, September 26, 2011. 28. 10 year-old male with left temporal tumor. Mock Brain Tumor Board, American Brain

Tumor Association Patient-Family Connections Meeting and Retreat, Chicago, IL, July 30, 2011.

29. IDH mutations in gliomas. University of Pittsburgh Neuropathology Division, Pittsburgh,

PA, October 27, 2010. 30. Molecular diagnostics in neuro-oncology: Making a tough job a little easier. Universidad

Autónoma, Barcelona, Spain, September 16, 2010. 31. Tele-lecture. CNS tumor genetics. iKaryos, Omaha, Nebraska, April 23, 2010. 32. Case 6: Neuromyelitis optica of the spinal cord clinically mimicking a neoplasm. Diagnostic

Slide Session, American Association of Neuropathology Annual Meeting, San Antonio, TX, June 2009.

33. Molecular diagnostics in neuropathology (It’s not just 1p/19q anymore!). Case Western

Reserve University, October 10, 2008. 34. Telepathology for intraoperative neuropathological consultations at an academic medical

center: A five-year report. University of Texas Southwest Medical Center, Neuropathology Division, Dallas, TX, October 2, 2007.

35. Frozen section interpretation by telepathology: Lessons learned from neuropathology.

Advancing Practice, Instruction and Innovation through Informatics 12th Annual Conference, Pittsburgh, PA, September 12, 2007.


36. Rapid in vitro studies of polyglutamine pathology. University at Pittsburgh Division of

Neuropathology Seminar Series, Pittsburgh, PA, March 21, 2002. 37. In vitro studies of repairs of pathology from mutated Huntingtin proteins. Neurology Grand

Rounds, Buffalo General Hospital, Buffalo, NY, November 29, 2001. Extramural Platform Presentations 1. The therapeutic potential of prostate apoptosis response–4 against glioma stem cells. Cancer

Stem Cell Conference, Cleveland, OH, August 18, 2014. 2. Mutant IDH1 suppresses apoptosis regulator par-4 in gliomas. 20th International Conference

on Brain Tumor Research and Therapy, Lake Tahoe, NV, July 21, 2014. 3. Predicting the likelihood of an IDH1 or IDH2 mutation in patients diagnosed with infiltrative

gliomas. American Association of Neuropathology Annual Meeting, Friday, Portland OR, June 13, 2014.

4. Effects of D-2-hydroxyglutarate on proliferation, apoptosis, autophagy, and oxidative stress

in gliomas. AANP Annual Meeting, Charleston SC, June 21, 2013. 5. Prospective comparison of FISH versus PCR-based LOH in the evaluation of gliomas for

1p/19q codeletion. American Association of Neuropathology Annual Meeting, Seattle, WA, June 25, 2011.

6. Isocitrate dehydrogenase 1 mutations are adverse prognostic markers in gangliogliomas.

XVIIth International Congress of Neuropathology, Salzburg, Austria, September 12, 2010. 7. Morphologic and molecular biomarkers in pilocytic astrocytomas. American Association of

Neuropathology Annual Meeting, San Antonio, TX, June 2009. Extramural Poster Presentations 1. Mutant IDH1 suppresses prostate apoptosis response-4 in gliomas. Fourth Quadrennial

Meeting of the World Federation of Neuro-Oncology, San Francisco, CA, November 23, 2013.

2. The oncometabolite (R)-2-hydroxyglutarate modulates stress-induced caspase activity in

glioma cells. AACR Annual Meeting, Chicago, IL, April 4, 2012. 3. Interplay between BRAF, p16, p53, and MIB1 in pediatric low grade gliomas. AACR

Annual Meeting, Chicago, IL, April 4, 2012. 4. Nonlinear relationship between EGFR amplification and response to temozolomide in

glioblastomas. Society for Neuro-Oncology Annual Meeting, Orange County, CA, November 17-20, 2011.


5. YKL-40 expression in high grade gliomas differs according to molecular subset. Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors, New Orleans, LA, October 22, 2009.

6. The prognostic value of Ki-67, p53, 1p36, and 9p21 in skull base chordomas. United States

and Canadian Academy of Pathology Annual Meeting, Boston, MA, March 2009. 7. Cryptic unbalanced t(4q;18q) in a pediatric patient. American Society for Investigative

Pathology Annual Meeting, San Diego, CA, April 2008. 8. Chordoid glioma: Molecular characterization of five cases. United States and Canadian

Academy of Pathology Annual Meeting, Denver, CO, March 2008. 9. Telepathology for intra-operative neuropathological consultations at an academic medical

center: A five-year report. XVI International Congress of Neuropathology, San Francisco, CA, September 2006.

10. Polyethylenimine (PEI)-mediated transfection of sympathetic neurons in vitro. Society for

Neuroscience Annual Meeting, Miami Beach, FL, October 1999. 11. BMP-7 signals through a novel intracellular FGF2-FGFR1 pathway in sympathetic neurons.

Society for Neuroscience Annual Meeting, Miami Beach, FL, October 1999. Intramural Presentations (University of Kentucky) 1. Lecture. Par-4 as a novel therapeutic strategy in brain cancer. CNTC & MCC-DT Joint

Seminar, Spring Series, January 14, 2014. 2. Lecture. IDH1 mutations in gliomas. Department of Molecular and Biomedical

Pharmacology Seminar Series, December 5, 2013. 3. Lecture and breakout session. Neuro-Oncology Update. 7th Annual Markey Cancer Center

Affiliate Network Meeting, April 26, 2013, 3-5 pm. 4. Lecture. Retrieval-based learning in medical school didactics. Medical Education Grand

Rounds, December 12, 2012. 5. Lecture. Par-4 the course in gliomas. Pathology Grand Rounds, Research Series, November

9, 2012. 6. Lecture. Par-4 as a therapeutic target in gliomas. COBRE symposium, B131 BBSRB,

October 26, 2012. 7. Lecture. Advanced molecular diagnostics in gliomas. Markey Research Series, September

5, 2012.


8. Lecture. Adventures in gliomas. KL2/Physician Scientist/Pilot Award Seminar, August 15, 2012.

9. Lecture. Why are IDH1 mutations favorable prognostic markers in gliomas? Molecular and

Cellular Biochemistry Summer Research Conference, June 6, 2012. 10. Poster. The oncometabolite (R)-2-hydroxyglutarate modulates stress-induced caspase

activity in glioma cells. Molecular and Cellular Biochemistry Summer Research Conference, June 5, 2012.

11. Invited lecture. Par-4 in gliomas. Cancer Cell Biology and Signaling Program Seminar

Series, May 10, 2012. 12. Invited lecture. A curveball about EGFR amplification in gliomas. Pathology Research

Seminar Series, January 6, 2012. 13. Invited lecture. The effect of IDH1/2 mutations on gliomas. MD/PhD Program student

monthly meeting, January 19, 2012. 14. Invited lecture. What's important to muscle pathologists. Muscle Forum, November 10,

2011. 15. Invited lecture. Autophagy and cancer. Department of Urology Grand Rounds, March 2,

2011. 16. Invited lecture. EGFR amplification in glioblastomas. Redox and Repair Group, January

25, 2011. 17. Invited lecture. Skeletal muscle pathology. Division of Rheumatology Grand Rounds,

January 12, 2011. 18. Invited lecture. Advances in molecular diagnostics in gliomas. Neurosurgery Grand

Rounds, December 2, 2010. 19. Invited lecture. Effects of IDH1/2 mutations on redox status in gliomas. Redox and Repair

Group, November 23, 2010. 20. Invited lecture. IDH mutations in glioneuronal tumors. Department of Pathology Grand

Rounds, November 5, 2010. 21. Poster. IDH1/2 mutation analysis in routine clinical testing of formalin-fixed paraffin-

embedded glioma tissues. CCTS 5th Annual Spring Conference, Tuesday, March 23, 2010. 22. Invited lecture. Neuro-oncology in the 21st century: Advances in molecular diagnostics and

telemedicine. Department of Neurology Grand Rounds, December 8, 2009.


23. Invited lecture. Isocitrate dehydrogenase mutations in gliomas. Department of Pathology Grand Rounds, December 4, 2009.

Intramural Co-Authored Abstracts (University of Kentucky) 1. Gilbert M, Liu Y, Sunkara M, Morris A, Pittman T, Kyprianou N, Horbinski C. Effects of

D-2-hydroxyglutarate on proliferation, apoptosis, autophagy, and oxidative stress in gliomas. Markey Cancer Center Research Day, April 15, 2013.

2. Ye Y , Yang L, Walsh M, Neltner J, Stromberg A, Bathke A, Horbinski C. Quantitative

measurement of oligodendroglioma histological features in predicting 1p/19q codeletion status. Markey Cancer Center Research Day, March 15, 2012.

3. Xing F, Wang C, Weiss H, Gal T, Durbin E, Neltner J, Horbinski C, Bensadoun E, Yang L.

Automatic, high throughput touching cell segmentation on digitized lung cancer pathology specimens. Markey Cancer Center Research Day, March 15, 2012.

4. Gilbert M, Liu Y, Morris A, Sunkara M, Kyprianou N, Horbinski C. The oncometabolite

(R)-2-hydroxyglutarate modulates stress-induced caspase activity in glioma cells. Markey Cancer Center Research Day, March 15, 2012.

MENTORING AND TEACHING MENTORING 1. Caleb Dawson, University of Kentucky undergraduate. Mentored on “IDH1 mutant gliomas

have fewer intratumoral intravascular thromboses” project, March 2014-present. 2. Laith Khoury, MD, University of Kentucky neurosurgery resident. Mentored on “IDH1

mutant gliomas have fewer intratumoral intravascular thromboses” project, March 2014-present.

3. Alice Luo, BS, first-year University of Kentucky medical student. Mentored on “Incidence of pediatric brain tumors in Appalachian Kentucky” project, February 2014-present.

Professional Student Mentored Research Fellowship Award, Center for Clinical and Translational Science, University of Kentucky, June 2014-May 2015.

4. Rachel Stewart, DO, Oncology Research Training for Surgeon-Scientists (T32 CA160003), July 2013-present.

Post-Doctoral Clinical Science First place, Markey Cancer Center Research Day, May 22, 2014.

5. Zoya Voronovich, University of Pittsburgh medical student. Mentored on “Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma,” 2012-2014.

6. Jonathan Mannas, University of Kentucky neurosurgery resident. Mentored on “Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma,” 2012-2014.

7. Meggen Walsh, DO, University of Kentucky pathology resident. Mentored on digital image analysis project of 1p/19q-codeleted gliomas (with Lin Yang as collaborator); presented


poster at 2012 AANP meeting in Chicago. Also mentored on “Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma,” 2012-2014.

8. Caitlin Latimer, MD, PhD, fourth-year University of Kentucky medical student. Mentored on case submission to the Diagnostic Slide Session at the 2013 American Association of Neuropathology Annual Meeting.

9. Jonathan Hobbs, BS, fourth-year University of Kentucky medical student. Mentored on several glioma research papers and presentations at the Markey Cancer Center Research Day and Duke University, June 2011-June 2012.

10. Kenneth Clark, MD, University of Pittsburgh neuropathology fellow. Mentored on glioma research paper and AANP 2012 platform presentation, for which Dr. Clark earned a $1,000 travel award, 2012.

Neuropathology fellowship, University of Kentucky 1. Janna Neltner, MD, July 2010-June 2012. Pathology resident rotations in neuropathology, University of Kentucky 1. Jeanette Ramos, MD, September 2011. 2. Robert Hilliard, MD, August 2010. Neurology resident rotations in neuropathology, University of Kentucky 1. Gregory Parks, MD, February 2012. 2. Fariha Zaheer, MD, February 2011. 3. Divya Singhal, MD, November 2010. 4. Veena Karandikar, MBBS, January 2010. 5. Donita Lightner, MD, October 2009. Ophthalmology resident rotations in ocular pathology, University of Kentucky 1. Christine Mollineaux, MD, July 2014-October 2014. 2. Joshua Evans, MD, March 2014-June 2014. 3. Clint Ellington, MD, November 2013-February 2014. 4. David Harris, MD, July 2013-October 2013. 5. Romulo Albuquerque, MD, March 2013-June 2013. 6. Paul Adam Frederick, MD, November 2012-February 2013. 7. Marla Davis, MD, July 2012-October 2012. 8. Joseph Childs, MD, March 2011-June 2012. 9. Deepta Ghate, MD, November 2011-February 2012. 10. D. Lucy Eakle, MD, July 2011-October 2011. 11. James Gullett, MD, March 2011-June 2011. 12. Martha Green, MD, November 2010-February 2011. 13. Kyle Thompson, MD, July 2010-October 2010. 14. Byron Cook, MD, March 2010-June 2010. Neurosurgery resident rotations in neuropathology, University of Kentucky 1. Barrett Brown, MD, February 2011.


TEACHING Lectures: Neurology Residents, University of Kentucky 1. CNS tumors. Department of Neurology Residents Didactic Series, 12:00-1:00 pm, February

8, 2012. 2. CNS tumors. Department of Neurology Residents Didactic Series, 12:00-1:00 pm, December

8, 2010. Lectures: Pathology Residents, Department of Pathology, University of Kentucky 1. Neuromuscular pathology. Department of Pathology Residents Didactic Series, 7:30-8:30

am, May 17, 2011. 2. CNS tumors part 3. Department of Pathology Residents Didactic Series, 7:30-8:30 am,

September 3, 2010. 3. CNS tumors part 2. Department of Pathology Residents Didactic Series, 7:30-8:30 am,

August 3, 2010. 4. CNS tumors part 1. Department of Pathology Residents Didactic Series, 7:30-8:30 am, June

8, 2010. Lectures: University of Kentucky Medical School 1. CNS tumors. MD 817, College of Medicine, HG-611, 8-9, April 14, 2014. 2. Demyelinating diseases and malformations. MD 817, College of Medicine, HG-611, 10-12,

March 20, 2014. 3. CNS tumors. MD 817, College of Medicine, HG-611, 2013. 4. CNS vascular diseases. Mechanisms of Disease and Treatment (PAT-823), College of

Medicine, CTW 014, 8-8:50 am, February 22, 2012. 5. Peripheral nerve and muscle disease. Mechanisms of Disease and Treatment (PAT-823),

College of Medicine, CTW 014, 9-9:50 am, February 22, 2012. 6. CNS tumors. Mechanisms of Disease and Treatment (PAT-823), College of Medicine, CTW

014, 9-9:50 am, February 17, 2012. 7. Peripheral nerve and muscle disease. Mechanisms of Disease and Treatment (PAT-823),

College of Medicine, CTW 014, 9-9:50 am, February 23, 2011. 8. CNS tumors. Mechanisms of Disease and Treatment (PAT-823), College of Medicine, CTW

014, 9-9:50 am, February 18, 2011. 9. CNS tumors. Mechanisms of Disease and Treatment (PAT-823), College of Medicine, CTW

014, 10-10:50 am, January 29, 2010.


10. Peripheral nerve and muscle disease. Mechanisms of Disease and Treatment (PAT-823),

College of Medicine, CTW 014, 11-11:50 am, January 29, 2010. Small Group Facilitator: University of Kentucky Medical School 1. Group Facilitator. CNS case studies. Mechanisms of Disease and Treatment (PAT-823),

College of Medicine, MN302, 8-8:50 am, February 25, 2011. 2. Group 7 Facilitator. CNS case studies. Mechanisms of Disease and Treatment (PAT-823),

College of Medicine, MN302, 10-10:50 am, February 1, 2010.

RESEARCH CURRENT GRANT SUPPORT

August 12, 2011- National Cancer Institute July 31, 2016 K08 CA155764

9.0 calendar months, $171,644 total costs ($158,930 direct costs) Principal Investigator: Horbinski C. The significance of isocitrate dehydrogenase mutations in gliomas Goal: Determine the effect of mutant IDH1 on oxidative stress, apoptosis, and autophagy in gliomas.

February 1, 2014- University of Kentucky Markey Cancer Center January 31, 2015 Cancer Center Support Grant Pilot Program $50,000 direct costs, no salary support Principal Investigator: Horbinski C.

Effect of IDH1 mutations on mitochondria and lipid metabolism in brain cancer Goal: Determine the roles that mitochondrial and lipid metabolism play in mediating mutant IDH1 glioma radiosensitivity.

January 1, 2014- University of Kentucky, Office of the Vice President for Research December 31, 2014 Research Support Grant program $4,966 direct costs, no salary support Principal Investigator: Horbinski C. Transgenic mouse modeling of IDH1-mutant gliomas

Goal: Create an inducible brain-specific mutant IDH1 mouse model. July 1, 2013- National Cancer Institute June 30, 2018 P30 CA177558

Cancer Center Support Grant 1.2 calendar months, $1,000,000 direct costs/year


Role: Biospecimen and Tissue Procurement Shared Resource Facility Director Principal Investigator: Evers BM. Goal: Support the ongoing research infrastructure, research programs, shared resources, developmental funds, and administration of the Markey Cancer Center to ensure the development of more effective approaches to cancer prevention, diagnosis, and therapy.

February 1, 2014- University of Kentucky Markey Cancer Center January 31, 2015 Cancer Center Support Grant Pilot Program 0.12 calendar months, $50,000 direct costs

Role: Oversee the creation of breast cancer tissue microarrays that will help evaluate the clinical significance of key markers in predicting breast cancer recurrence.

Principal Investigator: Tucker T. Evaluating potential markers for breast cancer recurrence: A retrospective cohort study

PENDING GRANT SUPPORT

January 1, 2015- American Cancer Society December 31, 2018 RSG TBE-127119

2.4 calendar months, $165,000 direct costs/year Principal Investigator: Horbinski C. The significance and therapeutic utility of Par-4 in gliomas Goals: Determine the mechanism(s) by which mutant IDH1 suppresses Par-4, evaluate the importance of Par-4 in preventing gliomagenesis, and explore Par-4 as a novel therapy in gliomas. Scored “Outstanding” at the TBE study section, recommended for funding as of 8/5/2014.

April 1, 2015- National Institute of Neurological Disorders and Stroke March 31, 2019 1R01NS091041-01 3.0 calendar months, $250,000 direct costs/year Principal Investigator: Horbinski C.

The impact and therapeutic significance of Par-4 in gliomas Goals: Determine the mechanism(s) by which mutant IDH1 suppresses Par-4, evaluate the importance of Par-4 in preventing gliomagenesis, and explore Par-4 as a novel therapy in gliomas.


COMPLETED GRANT SUPPORT

July 1, 2008- American Brain Tumor Association June 30, 2010 Basic Research Fellowship 8.4 calendar months, $40,000 salary support/year Principal Investigator: Horbinski C. Biomarkers of juvenile pilocytic astrocytoma

Goal: Determine the relative impact of key histologic and molecular variables in predicting the outcome of pediatric pilocytic astrocytomas.

January 1, 2011- Peter and Carmen Lucia Buck Training Program in Translational December 31, 2011 Clinical Oncology $25,000 direct costs, no salary support Principal Investigator: Horbinski C. The significance of isocitrate dehydrogenase mutations in gliomas

Goal: Determine the effect of mutant IDH1 on oxidative stress, apoptosis, and autophagy in gliomas.

June 1, 2010- University of Kentucky College of Medicine May 31, 2013 Physician Scientist Program 9.0 calendar months, $75,000 direct costs/year Principal Investigator: Horbinski C. The significance of isocitrate dehydrogenase mutations in gliomas


(Awarded but had to decline due to 100% overlap with K08) July 1, 2010- American Cancer Society June 30, 2015 MRSG TBE-121465 Mentored Research Scholar Grant

9.0 calendar months, $135,000 direct costs/year Principal Investigator: Horbinski C. The significance of isocitrate dehydrogenase mutations in gliomas


July 1, 2012- National Institute of General Medical Sciences June 30, 2014 2P20 RR020171 Center of Biomedical Research Excellence on the Molecular Basis of Human

Disease $50,000 direct costs/year, no salary support

Principal Investigator of Subproject: Horbinski C. (Hersh L. was PI on the overarching multi-PI grant) Par-4 as a therapeutic target in gliomas


Goals: Identify the signaling pathway by which mutant IDH1 regulates Par-4 expression in gliomas, and determine the therapeutic potential of Par-4 modulation in gliomas.

SERVICE

NATIONAL INSTITUTE OF HEALTH — Early Career Reviewer, 2012-present

(Clinical Oncology study section CONC, 2/10/2014) UNIVERSITY AND MEDICAL SCHOOL

University of Kentucky — College of Medicine Faculty Council, September 1, 2014-present. — Director, Molecular Anatomic Pathology, August 2011-present.

— Director, Brain Tumor Bank, November 2010-present. — Executive Steering Committee, Biobank and Research Registry, November 2013-

present. — Co-Director, Muscle Tissue Bank, November 2010-present. — Medical Scientist Training Program Internal Advisory Committee, Fall 2012-

present. — Pharmacogenomics Endowed Chair Search Committee, Department of Pharmacy

Practice and Science, June 2014-present. — Thesis Advisory Committees

• Hyun-Jung Kim (Xianglin Shi lab), graduate student, January 2011-present.

• Joanne Collazo (Natasha Kyprianou lab), graduate student, August 2011-June 2014.

• Kristin Linscott (Joseph Chappell lab), MD/PhD student, August 2013-present.

• Erin Wolf-Horrell (John D’Orazio lab), MD/PhD student, November 2013-present.

— Outside thesis examiner • Alessandra Mattei, PhD candidate in Pharmaceutical Sciences (mentor

Tonglei Li), June-July 2012. • Lu Miao, PhD, candidate in Toxicology (mentor Daret St. Clair), July

2013. — Molecular Diagnostics workgroup, Oncology subcommittee, Department of

Pathology, December 2010-present. — Center for Clinical and Translational Sciences

• Reviewer for pilot grant applications, 2012-present. — Kentucky Lung Cancer Research Program

• Reviewer for pilot grant applications, 2012-present. — Postdoctoral Committee, September 2010-April 2013.

• Panelist - Lost in translation: What a PI expects and a postdoc needs. November 14, 2012.


• Poster judge - Postdoctoral Research Day, December 7, 2011. • Poster judge - Postdoctoral Research Day, December 7, 2010. • Panelist - Negotiating a startup package: The devil is in the details.

Nursing Building, Room 511, 4:00-5:00pm, October 20, 2010.

Markey Cancer Center — Director, Markey Cancer Center Biospecimen and Tissue Procurement Shared

Resource Facility, June 2013-present. — Co-coordinator, 1st Annual Neuro-Oncology Symposium, November 8, 2012. — Markey Cancer Center Research Review Committee, May 1, 2012-April 30,

2015. — Internal Advisory Committee, NCI P01: Systems biochemistry in lung cancer:

Toward a mechanistic understanding of NSCLC, 2014-present. — Markey Cancer Center Research Day

• Poster judge - May 22, 2014. • Poster judge - May 16, 2012. • Poster judge - March 22, 2011.

— Neuro-Oncology Search Committee, January 2010-June 2011. — Nanotechnology and Cancer Committee, December 2009-present. — Trainee Evaluation Committee, Cancer Biology/Surgical Oncology T32

program, November 2013-present.

University of Pittsburgh — Internal reviewer of Neuroradiology Fellowship Program, October 2008. — Coordinator, Multidisciplinary Neurology, Neuroradiology, Neurosurgery, and

Neuropathology Case Correlation Conference, Spring 2008-Fall 2008. — Internal reviewer of Gastroenterology Fellowship Program, October 2007.

PROFESSIONAL ORGANIZATIONS

American Association of Neuropathologists — Diagnostic Slide Session Charter Member, 2014. — Co-Chair, Platform Session on Glial Tumors, 90th Annual Meeting, Portland, OR,

June 13, 2014. — Awards Committee Member, 89th Annual Meeting, Charleston, SC, June 2013. — Co-Chair, Platform Session on Tumors, 88th Annual Meeting, Chicago, IL June

2, 2012. — Awards Committee Member, 88th Annual Meeting, Chicago, IL, June 2012. — Awards Committee Member, 87th Annual Meeting, Seattle, WA, June 2011. — Co-Chair, Platform Session on Glial Tumors, 86th Annual Meeting, Philadelphia,

PA, June 2010. — Awards Committee Member, 86th Annual Meeting, Philadelphia, PA, June 2010.

Canadian Brain Tumor Consortium

— External abstract judge, Young Investigator Award, Canadian Neuro-Oncology Annual Meeting, Vancouver, BC, Feb 9-12th, 2012.


Children’s Oncology Group — Central pathology reviewer for clinical trial ACNS1221. A phase II study for the

treatment of non-metastatic desmoplastic medulloblastoma in children less than 4 years of age. 2012-present.

Pediatric Brain Tumor Consortium

— Low grade glioma committee member, 2013-present.

Society for Neuro Oncology — Abstract judge, Society for Neuro Oncology Annual Meeting, 2014.

United States and Canadian Academy of Pathology

— Co-Chair, Platform Session on Neuropathology, 2012 Annual Meeting, Vancouver, BC March 20, 2012.

EDITORIAL SERVICES 1. Editorial Board, Brain Pathology, 2013-present. 2. Editorial Board, Acta Neuropathologica, 2012-present.

3. Editorial Board, Journal of Neuropathology and Experimental Neurology, 2011-present.

4. Ad hoc reviewer, Diagnostic Pathology, 2014-present. 5. Ad hoc reviewer, Brain Research Bulletin, 2014-present. 6. Ad hoc reviewer, Journal of Neuroscience Research, 2014-present. 7. Ad hoc reviewer, Neuro-Oncology, 2013-present. 8. Ad hoc reviewer, Laboratory Investigation, 2013-present. 9. Ad hoc reviewer, Human Mutation, 2013-present.

10. Ad hoc reviewer, Acta Neuropathologica Communications, 2013-present. 11. Ad hoc reviewer, PLoS Biology, 2013-present. 12. Ad hoc reviewer, PLoS One, 2013-present. 13. Ad hoc reviewer, CNS Oncology, 2013-present. 14. Ad hoc reviewer, Clinical Cancer Research, 2012-present. 15. Ad hoc reviewer, Lancet Oncology, 2012-present. 16. Ad hoc reviewer, Autophagy, 2012-present. 17. Ad hoc reviewer, Journal of Neuro-Oncology, 2012-present. 18. Ad hoc reviewer, Journal of Molecular Diagnostics, 2012-present. 19. Ad hoc reviewer, Genes, Chromosomes and Cancer, 2011-present. 20. Ad hoc reviewer, Cancer Epidemiology, Biomarkers and Prevention, 2011-present. 21. Ad hoc reviewer, Cancer Research, 2009-present. 22. Ad hoc reviewer, Brain Pathology, 2010-2013. 23. Ad hoc reviewer, Acta Neuropathologica, 2010-2012.


PERSONAL STATEMENT

I am a physician-scientist who is board-certified in anatomic pathology and neuropathology. I completed a combined MD/PhD program at the University at Buffalo, The State University of New York, followed by anatomic pathology residency and neuropathology fellowship training at the University of Pittsburgh Medical Center (UPMC). I joined the pathology faculty at the University of Kentucky (UK) in 2009 and was recently promoted to Associate Professor with Tenure.

Although I am still relatively early in my research career, it has already been highly productive. To date I have 57 papers in publication or in press, and am the first or senior author on 35 of them. Within UK I have been very resourceful, translating findings to gliomas that had originally been discovered by UK researchers studying other cancers. As a result, I now have several promising avenues of novel research on glioma metabolism, apoptosis, and stem cell biology. I have successfully competed for intramural and extramural funding, including an NCI K08 that scored in the top percentile and an American Cancer Society Research Scholar grant that was recently recommended for funding. I currently have an R01 under review and am working towards two more submissions. I have collaborated with a variety of brain tumor researchers at several prestigious institutions, including Cleveland Clinic, Ohio State University, Duke University, and the University of California, San Francisco. All this work has earned me an international reputation in neuropathology and neuro-oncology circles as a team-oriented, energetic physician-scientist.

I have developed an extended and diverse background in biobanking since my days as a pathology resident, especially of brain tumors and postmortem CNS tissues. I founded my own brain tumor bank at UK in 2010; we recently collected our 300th snap-frozen case. Because of my proven ability to manage a robust biobank, in June 2009 I was asked by the Markey Cancer Center Director, Dr. Mark Evers, to assume directorship of the Biospecimen and Tissue Procurement Shared Resource Facility for the entire Markey Cancer Center (http://ukhealthcare.uky.edu/markey/biospecimen/). As director, I instituted a variety of reforms that quadrupled our average monthly collections and increased utilization of the facility by several fold, even while dramatically improving our financial health. Now we are establishing a statewide tumor biorepository that collects samples from hospitals throughout Kentucky, which will be an invaluable resource for UK.

I also have a great deal of expertise in molecular diagnostics. From my days at UPMC to the present, I have handled molecular testing on over 1,000 gliomas. Because of this background, one of my mandates when coming to UK was to create a brand-new Molecular Anatomic Pathology Laboratory. We now offer over a dozen clinical molecular tests for a variety of cancers, including an excellent panel for adult gliomas (http://pathology.med.uky.edu/molecular-anatomic-pathology). All these tests have improved the department’s finances by hundreds of thousands of dollars each year. We are still adding more, with a special new focus on next-generation sequencing.

In sum, I have a rare combination of research, biobanking, molecular diagnostics, and surgical neuropathology expertise, including strong track records of successful leadership and trainee mentoring. Furthermore, I provide a rigorous tissue-based perspective that is essential for a world-class brain tumor institute, but is hard to find since there are very few neuropathologists

http://ukhealthcare.uky.edu/markey/biospecimen/

http://pathology.med.uky.edu/molecular-anatomic-pathology

http://pathology.med.uky.edu/molecular-anatomic-pathology


who specialize in tumors and are also principal investigators. My aim is to integrate my skill set into a powerful multidisciplinary team of physicians and scientists who are committed to improving the care of people afflicted with brain tumors. In addition to elevating the impact of my own research, I want to direct a brain tumor core facility, providing the team with an outstanding resource that will greatly enhance the caliber of research, including supporting large extramurally-funded multi-investigator projects. It is my ultimate desire to, at the end of my career, look back and be satisfied that all my efforts have helped reduce suffering and tragedy. [9/3/2014]

Documents

CRAIG M HORBINSKI, MD P D PERSONAL NFORMATION ......17. Burikhanov R, Shresta-Bhattarai T, Qiu S, Shukla N, Hebbar N, Lele S, , Horbinski C *Rangnekar VM. Novel mechanism of apoptosis